01/11/2023 |
1Q: Refocused Business Cutting Expenses, Progressing Trials
|
MST Access |
09 /10/2023 |
Pharmaxis evolves into Syntara: sells mannitol unit; sharpening operational focus and cutting costs
|
MST Access |
06/10/2023 |
Restructured to Smaller, More Agile Drug Developer
|
Morgans |
05/09/2023 |
Positive PXS-5505 Preclinical Data Published in Peer-Reviewed Journal
|
MST Access |
22/8/2023 |
Clinical-stage pipeline continues to advance
|
Morgans |
14/8/2023 |
Pharmaxis -Meaningful Impact on Bone Marrow in Myelofibrosis Study
|
Bioshares |
21/6/2023 |
Progressing to Next Stage in Scarring and Myelofibrosis
|
Taylor Collison |
06/06/2023 |
Mixed Results from Pharmaxis' Scar Treatment Study
|
Bioshares |
25/05/2023 |
Pleasing Results from Established Scars, Phase 1c – More to Come
|
MST Access |
05/05/2023 |
3Q: Cash Balance Comfortable as Key Trials Proceed in Tandem
|
MST Access |
01/05/2023 |
Pharmaxis Phase II Trial Results Approaching
|
Bioshares |
13/04/2023 |
Useful FDA Feedback Paves Way for New Arm of Lead Clinical Trial
|
MST Access |
30-03-2023 |
Raising PXS-5505 Profile in New Indication, Synergies with SOC
|
MST Access |
28-03-2023 |
Pharma's Market
|
Bell Potter |
24-02-2023 |
Pharmaxis: A Re-Rating Approaching?
|
Bioshares |
20-02-2023 |
2QFY23 – news flow plentiful in 2023 with data readouts from two major trials
|
MST Access |
27-12-2022 |
Top 6 Stock Picks for 2023: Will 2023 be the Breakout Year for Pharmaxis?
|
Bioshares |
09-11-2022 |
1QFY23 Release Shows Diverse Pipeline Continuing to Deliver News Flow
|
MST Access |
04-11-2022 |
Pharmaxis Releases Initial Data in Myelofibrosis
|
Bioshares |
07-10-2022 |
Encouraging initial efficacy data, adding new programs
|
Taylor Collison |
19-09-2022 |
Pharmaxis: Can PXS-6302 'Un-scar the
Scar'?
|
Bioshares |
12-09-2022 |
Pharmaxis Repurposes PXS-4728 for Parkinson's Disease
|
Bioshares |
02-09-2022 |
New collaboration to study PXS-4728 for early neurodegenerative treatment |
MST Access |
16-August-2022 |
Building up its short-term cash position |
Morgans |
05-08-2022 |
Pharmaxis Sells Orbital Technology for US$5 Million
|
Bioshares |
15-June-2022 |
Clinical trials on track; news flow ahead |
MST Access |
12-April-2022 |
Following the Science |
Morgans |
08-April-22 |
PXS-5505 and PXS-6320 R&D Days |
Taylor Collison |
15-Feb-22 |
Pharmaxis Update |
Bioshares |
31-Jan-22 |
Making tracks with concurrent trials; 2Q results announced |
MST Access |
6-Dec-21 |
New capital extends cash runway |
MST Access |
30-Nov-21 |
Initiation Report: Pharmaxis - Exploring Efficacy in Cancer and Fibrosis |
Taylor Collison |
24-Nov-21 |
Updated report |
Emerald |
12-Nov-21 |
New indication for PXS-5505 |
MST Access |
1-Nov-21 |
Initiation of Coverage |
MST Access |
18-May-21 |
Initial report |
Emerald |
19-Apr-21 |
Karst Peak Continues Investment in Austalia Biotech |
Bioshares |
15-Feb-21 |
Pharmaxis Makes First Commercial Bronchitol Shipment to USA |
Bioshares |
13-Feb-21 |
1H21 – Result Summary |
Bell Potter |
7-Jan-21 |
FDA approval for Bronchitol revamps the business, improves outlook |
Bell Potter |
3-Nov-20 |
Bronchitol FDA Approval a Turning Point for Pharmaxis |
Bioshares |
7-Sep-20 |
Boehringer Ends Development of Pharmaxis Compound |
Bioshares |
7-Sep-20 |
BI terminates agreement, discontinues |
Bell Potter |
19-Aug-20 |
FDA clears IND for myelofibrosis study |
Bell Potter |
13-Aug-20 |
FY20 Audited Results - No Material Change |
Bell Potter |
10-Aug-20 |
A Big Six Months Ahead for Pharmaxis |
Bioshares |
5-Aug-20 |
Key catalysts expected in Q4CY20 |
Bell Potter |
22-May-20 |
COVID-19 impacting timing for key catalysts |
Bell Potter |
4-May-20 |
Pharmaxis - Multiple Assets to Drive Value |
Bioshares |
24-Feb-20 |
Pharmaxis Remains Confident of Securing LOXL2 Deal |
Bioshares |
13-Feb-20 |
1H20 Audited Results - No Material Change |
Bell Potter |
6-Feb-20 |
Down but not out, with turnaround prospects strong in CY20 |
Bell Potter |